Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK: Aspirin, dipyridamole and aspirin-dipyridamole

PharmacoEconomics

Volumn 16, Issue 5 II, 1999, Pages 577-593

  Chambers, Mike ^a,c   Hutton, John ^a   Gladman, John ^b  

^a MEDTAP International   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c MEDTAP International   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE;

ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; ASPIRIN; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIPYRIDAMOLE; DRUG COMBINATIONS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MODELS, ECONOMIC; PLATELET AGGREGATION INHIBITORS; RECURRENCE;

EID: 0032693988     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199916050-00013     Document Type: Article

References (52)

1. Wade DT, Stroke (acute cerebrovascular disease). In: Stevens A, Raftery J eds. Health care needs assessment; the epidemiologically based needs assessment reviews. Vol. I. Oxford: Radcliffe Medical Press, 1994
2. Office of Health Economics (OHE). Office of Health Economics. Stroke 1988
3. Isard PA, Forbes JF. The cost of stroke to the National Health service in Scotland. Cerebrovasc Dis 1992; 2: 47-50
4. Bergman L, ven der Meulen JHP, Limburg M, et al. Cost of medical care after first-ever stroke in the Netherlands. Stroke 1995; 26: 1830-6
5. Terent A, Marke L-A, Asplund K, et al. Costs of stroke in Sweden. A national perspective. Stroke 1994; 25: 2363-9
6. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke 1996; 27: 1459-66
7. Porsdal V, Boysen G. Cost-of illness studies of stroke. Cerebrovasc Dis 1997; 7: 258-63
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I; prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMI 1994; 308: 81-106
9. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7
10. Gent M, Easton JD, Hachinski VC, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989 Jun 3; 1 (8649): 1215-20
11. The ESPS Group. The European Stroke Prevention Study (ESPS): Principal End-points. Lancet 1987 Dec 12; 2 (8572); 1351-4
12. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143: 1-13
13. The ESPS-2 Group. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 1997; 151: SI-S77
14. CAPRIE steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 1996; 348: 1329-39
15. Royal College of Physicians of Edinburgh. Consensus conference on the medical management of stroke consensus statement [online]. Available from: URL: http://www.rcpc.ac.uk/round /stroke.html [accessed 1998 May 27]
16. Oster G, Huse DM, Lacey MJ, et al. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 1994; 25: 1149-56
17. Scott G, Scott HM. Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis. Pharmacoeconomics 1997; 12 (6): 667-74
18. Alexandrov AV, Smurawska LT, Bartle W, et al. Cost considerations in the pharmacological prevention and treatment of stroke. Pharmacoeconomics 1997; 11: 408-18
19. Weinstein MC, Fineberg HV. Clinical decision analysis. WB Saunders, Philadelphia 1980
20. DII/ABPI Guidelines for the economic evaluation of pharmaceuticals. Department of Health, May 1994
21. Burn J. The outcome of a first stroke: the Oxford Community Stroke Project. MD thesis: University of Oxford 1991
22. Burn J, Dennis M, Bamford J, et al. Long-term risk of recurrent stroke after a first-ever stroke: the Oxfordshire Community Stroke Project. Stroke 1994; 25: 333-7
23. Rankin J. Cerebral vascular accidents in people over the age of 60, II Prognosis. Scott Med J 1957; 2: 200-15
24. van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-7
25. Office of Population Census and Surveys (OPCS). Mortality statistics 1991: Cause. HMSO 1993; Series DH2(18)
26. Chartered Institute of Public Finance and Accountancy (CIPFA). Health Database 1995. Volume 3A Provider Database: Activity Costs Analysis CIPFA 1995
27. Netten A, Dennett J, editors. Unit costs of health and social care 1996. Personal Social Services Research Unit. University of Kent, 1996
28. CHKS. Acute Care 95: Healthcare Resource Groups, National Statistics 1994/95. CHKS Ltd, Alcester, Warwickshire, UK 1995
29. MIMS Monthly Index of Medical Specialities. December 1996
30. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274 (23): 1839-45
31. Overell J, Walker A, Weir C, et al. The cost effectiveness of clopidogrel and the combination of aspirin and dipyridamole in stroke prevention. Cerebrovasc Dis 1999; 9 (1 Suppl.): 66
32. Buxton M, Drummond M, Van Hout B, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Economics 1997; 6: 217-27
33. Glick H, Kinosian B, Schulman K. Decision analytic modeling: some uses in the evaluation of new pharmaceuticals. Drug Int J 1994; 28: 691-707
34. Brown RD, Whisnant JP, Sicks RD, et al. Stroke incidence, prevalence and survival. Secular trends in Rochester, Minnesota, through 1989. Stroke 1996; 27: 373-80
35. Sacco RL, Wolf PA, Kennel WB, et al. Survival and recurrence following stroke: the Framingham study. Stroke 1982; 13: 290-5
36. Petty GW, Brown RD, Sicks J, et al. Survival and recurrence after first cerebral infarction in Rochester, Minnesota, 1975-89. Cerebrovasc Dis 1996; 6 Suppl. 2: 6-7
37. Sacco RL, Shi T, Zamanillo MC, et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44: 626-34
38. Easton JD. Epidemiology of stroke recurrence. Cerebrovasc Dis 1997; 7 Suppl. 1: 2-4
39. Dombovy ML, Basford JR, Whisnant JP, et al. Disability and use of rehabilitation services following stroke in Rochester, Minnesota, 1975-1979. Stroke 1987; 18: 830-6
40. Matchar DB, McCrory DC, Barnett HJM, et al. Medical treatment for stroke prevention. Ann Int Med 1994; 121: 41-53
41. Hart RG, Harrison MJG. Aspirin wars: the optimal dose of aspirin to prevent stroke. Stroke 1996; 27: 585-7
42. Barnett HJM, Kaste M, Meldrum H, et al. Aspirin dose in stroke prevention. Beautiful hypotheses stain by ugly facts. Stroke 1996; 27: 588-92
43. Department of Health and Human Services (DHHS), Food and Drug Administration, 21 CFR Part 243 [docket No. 77N-094A], Internal analgesic, antipyretic and antirheumatic drug products for over-the-counter human use: final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid products. Federal Register 1998; 63 (205); 56802-19
44. De Schryver ELLM on behalf of the ESPRIT study group. ESPRIT: mild anticoagulation, acetylsalicylic acid plus dipyridamole or acteylsalicylic acid alone after cerebral infarction of arterial origin. Cerebrovasc Dis 1998; 8 Suppl. 4: 83
45. Department of Heallh (DH). Hospital Episode Statistics: Volume I. 1993-94. UK Department of Health 1995
46. Pollock S. A district stroke service. Br J Hosp Med 1997; 57: 224-8
47. Becch R, Ratcliffe M, Tilling K, et al. on behalf of the participants of the European Study of Stroke Care. Hospital Services for Stroke Care: a European perspective. Stroke 1996; 27: 1958-64
48. Gladman J, Whynes D, Lincoln N, for the DOMINO group, Cost comparison of domiciliary and hospital-based stroke rehabilitation. Age Ageing 1994; 23: 241-5
49. Young J, Forster A. Day hospital and home physiotherapy for stroke patients: a comparative cost-effectiveness study. J Royal Coll Phys 1993; 27: 252-8
50. Gladman J, Albazzaz M, Barer D. A survey of survivors of acute stroke discharged from hospital to private nursing homes in Nottingham. Health Trends 1991; 23: 158-60
51. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. BMJ 1997; 314: 1151-9
52. Wilkinson PR, Wolfe C, Warburton FG, et al. A long-term follow-up of stroke patients. Stroke 1997; 28: 507-42